Cargando…

Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma

Chronic active hepatitis B infection (HBV) has been implicated in lymphomagenesis of non-Hodgkin lymphoma (NHL). Treatment of cancer including NHL with chemotherapy or immunotherapy can lead to HBV reactivation in previously infected patients. Serological testing of HBV prior to initiation of this t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelling, Matthew, Sokol, Lubomir, Dalia, Samir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852364/
https://www.ncbi.nlm.nih.gov/pubmed/29606020
http://dx.doi.org/10.1177/1073274818767879
_version_ 1783469817505775616
author Kelling, Matthew
Sokol, Lubomir
Dalia, Samir
author_facet Kelling, Matthew
Sokol, Lubomir
Dalia, Samir
author_sort Kelling, Matthew
collection PubMed
description Chronic active hepatitis B infection (HBV) has been implicated in lymphomagenesis of non-Hodgkin lymphoma (NHL). Treatment of cancer including NHL with chemotherapy or immunotherapy can lead to HBV reactivation in previously infected patients. Serological testing of HBV prior to initiation of this therapy is recommended by several national and international medical agencies and expert panels. Patients with positive hepatitis B surface antigen (HBsAg) and anti-hepatitis B core antibody (anti-HBc ab) need to start antiviral therapy with entecavir or tenofovir prior to initiation of chemotherapy or immunotherapy and continue this treatment for 6 to 12 months after completion of cancer therapy to avoid late HBV reactivation. Monitoring of HBV DNA viral load and liver function tests should be done during cancer therapy in infected patients. Hepatitis B infection vaccination resulted in decreases prevalence of HBV virus carriers and decreased incidence of virus-induced malignancies.
format Online
Article
Text
id pubmed-6852364
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-68523642019-11-22 Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma Kelling, Matthew Sokol, Lubomir Dalia, Samir Cancer Control Review Chronic active hepatitis B infection (HBV) has been implicated in lymphomagenesis of non-Hodgkin lymphoma (NHL). Treatment of cancer including NHL with chemotherapy or immunotherapy can lead to HBV reactivation in previously infected patients. Serological testing of HBV prior to initiation of this therapy is recommended by several national and international medical agencies and expert panels. Patients with positive hepatitis B surface antigen (HBsAg) and anti-hepatitis B core antibody (anti-HBc ab) need to start antiviral therapy with entecavir or tenofovir prior to initiation of chemotherapy or immunotherapy and continue this treatment for 6 to 12 months after completion of cancer therapy to avoid late HBV reactivation. Monitoring of HBV DNA viral load and liver function tests should be done during cancer therapy in infected patients. Hepatitis B infection vaccination resulted in decreases prevalence of HBV virus carriers and decreased incidence of virus-induced malignancies. SAGE Publications 2018-04-01 /pmc/articles/PMC6852364/ /pubmed/29606020 http://dx.doi.org/10.1177/1073274818767879 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Kelling, Matthew
Sokol, Lubomir
Dalia, Samir
Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma
title Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma
title_full Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma
title_fullStr Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma
title_full_unstemmed Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma
title_short Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma
title_sort hepatitis b reactivation in the treatment of non-hodgkin lymphoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852364/
https://www.ncbi.nlm.nih.gov/pubmed/29606020
http://dx.doi.org/10.1177/1073274818767879
work_keys_str_mv AT kellingmatthew hepatitisbreactivationinthetreatmentofnonhodgkinlymphoma
AT sokollubomir hepatitisbreactivationinthetreatmentofnonhodgkinlymphoma
AT daliasamir hepatitisbreactivationinthetreatmentofnonhodgkinlymphoma